22 August 2025 | 9:07PM HKT In line with earlier profit alert, Pharmaron reported 2Q25 revenue of Rmb3.34bn, reflecting a robust +13.9% y/y increase, primarily supported by sustained momentum in CMC services (+17.4% y/y), and a sequential improvement of +7.9% q/q, driven by the solid growth in laboratory services (+9.6% q/q), particularly bioscience services. Adjusted net profit reached Rmb 406mn, +15.6% y/y and +16.3% q/q, with adjusted net margin improving to 12.2% from 11.3% in 1Q25, supported by margin ...